About Riddhima Chakraborty
Riddhima is a financial journalist with a passion for analyzing financial instruments. With a master's degree in economics, she helps investors make informed investment decisions through her insightful commentaries.
Recent Articles By Riddhima Chakraborty
5 Fallen Stocks to Continue to Avoid This November
While the October inflation report came in better than expected, it is far from the Fed’s target. Amid rising recession odds, consumer sentiment is declining. Therefore, fundamentally weak stocks NVIDIA (NVDA), Carnival Corporation (CCL), AMC Entertainment (AMC), Peloton Interactive (PTON), and Mullen Automotive (MULN), which have been slumping in price, might be best avoided now. Keep reading…
HBI Stock: Is It a Bargain at $7 per Share?
Hanesbrands’(HBI) shares are trading near their 52-week low of $6.40, slumping more than 55% year-to-date. The stock closed its last trading session at $7.04. Moreover, several analysts have downgraded the stock in the recent past. Let’s find out if HBI is a bargain at its current price…
2 Dividend Stocks That Can See Your Portfolio Through Tough Times and Beyond
The market has been under pressure amid high inflation, rising interest rates, and a slowing economy. Amid lingering macro headwinds, dividend investing could help investors ensure a steady income stream. Therefore, quality dividend stocks, CVS Health (CVS) and Spok Holdings (SPOK) could be ideal investments to navigate through tough times and beyond. Keep reading…
1 Stock to Make Sure You Dump From Your Portfolio This Fall
Redfin Corporation (RDFN) laid off its employees for the second time this year, citing declining demand in the housing industry. Furthermore, the stock has lost more than 85% in price year-to-date. Amid declining homebuyer sentiments, RDFN might be best avoided. Read on…
2 Stocks to Buy That Aren't as Expensive as You'd Think
Amid the broader market sell-off this year, value investing has been gaining traction. Value stocks have been outperforming growth recently. Therefore, investors could consider buying quality stocks Pfizer (PFE) and Cisco Systems (CSCO), which are less expensive than thought. Keep reading…
Is It Worth Taking a Gamble on SoFi Stock in 2022?
SoFi Technologies’ (SOFI) lending business is struggling amid the persistently high inflation and the Fed’s consecutive rate hikes. The stock has lost more than 60% in 2022. With the central bank far from ending its rate hike campaign, will it be worth owning SOFI? Keep reading…
2 Stocks You Can Buy This Week for Under $100
Lingering macroeconomic issues have led to significant volatility in the market. While inflation is still at a multi-decade high, the October inflation report showing signs of cooling price pressures has raised optimism. Therefore, investors could scoop up quality dividend-paying stocks Comcast (CMCSA) and Texas Roadhouse (TXRH), trading under $100, to ensure a steady income stream. Keep reading…
Is Gilead Sciences Still a Buy Post COVID-19?
Gilead Sciences’ (GILD) popular covid product Veklury (Remdisivir) witnessed declining sales in the post-pandemic era. However, the company’s top line, excluding Veklury, has seen steady growth. Moreover, despite ongoing market volatility, the stock has registered stable gains. So, let’s find out if GILD is still a buy in the post-covid era…
2 Stocks Every Investor Should Make Room in Their Portfolio For
Despite the October inflation report showing a slowdown in the price increases, the U.S. economy is still surrounded by deep uncertainty. Moreover, the IMF has warned of further challenges ahead. Therefore, quality stocks Johnson & Johnson (JNJ) and Coca-Cola (KO), which have a solid dividend-paying record, could be ideal additions to your portfolio. Keep reading…